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Abstract 
Lower‑extremity arterial disease (LEAD) is a major endemic disease with an alarming increased prevalence worldwide. 
It is a common and severe condition with excess risk of major cardiovascular events and death. It also leads to a high 
rate of lower‑limb adverse events and non‑traumatic amputation. The American Diabetes Association recommends 
a widespread medical history and clinical examination to screen for LEAD. The ankle brachial index (ABI) is the first 
non‑invasive tool recommended to diagnose LEAD although its variable performance in patients with diabetes. The 
performance of ABI is particularly affected by the presence of peripheral neuropathy, medial arterial calcification, 
and incompressible arteries. There is no strong evidence today to support an alternative test for LEAD diagnosis in 
these conditions. The management of LEAD requires a strict control of cardiovascular risk factors including diabetes, 
hypertension, and dyslipidaemia. The benefit of intensive versus standard glucose control on the risk of LEAD has not 
been clearly established. Antihypertensive, lipid‑lowering, and antiplatelet agents are obviously worthfull to reduce 
major cardiovascular adverse events, but few randomised controlled trials (RCTs) have evaluated the benefits of these 
treatments in terms of LEAD and its related adverse events. Smoking cessation, physical activity, supervised walking 
rehabilitation and healthy diet are also crucial in LEAD management. Several advances have been achieved in endo‑
vascular and surgical revascularization procedures, with obvious improvement in LEAD management. The revasculari‑
zation strategy should take into account several factors including anatomical localizations of lesions, medical history 
of each patients and operator experience. Further studies, especially RCTs, are needed to evaluate the interest of 
different therapeutic strategies on the occurrence and progression of LEAD and its related adverse events in patients 
with diabetes.
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Introduction
Lower extremity arterial disease (LEAD) is a major 
manifestation of systemic atherosclerosis with severe 
associated cardiovascular, lower limb and functional 
complications. It results from a partial or complete 
obstruction of one or more lower limb arteries. The first 
known presentation of lower-limb vascular disease was 
reported in 1831 in a horse that had a lameness thought 
to be due to femoral artery occlusion of the posterior 
limb. Similar symptom was described few years later in 
humans and characterized as an intermittent claudication 
(IC). Further investigations showed that IC was linked to 
muscle ischemia, induced by walking, and considered it 
as a clinical manifestation of LEAD. During the last dec-
ades, a large body of data have reported that LEAD was 
associated with increased risk of non-traumatic lower 
limb amputation (LLA), cardiovascular disease (CVD), 
and mortality [1–3]. Nowadays, LEAD has become an 
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emerging public health burden with an endemic progres-
sion worldwide resulting from a demographic expansion, 
population aging and increasing prevalence of tobacco 
smoking habits, hypertension, dyslipidaemia, and type 
2 diabetes [4–6]. Yet, LEAD is particularly frequent in 
diabetic patients with worse outcomes, especially the 
risk of LLA, four to five times higher, compared with 
non-diabetic subjects [1, 2, 7–9]. Despite its severity, 
LEAD remains less studied than other diabetic vascu-
lar complications; and only few randomised controlled 
trials (RCTs) have dealt with major lower-limb adverse-
events as pre-specified endpoints. Therefore, widespread 
reviews of the literature dedicated to LEAD are scarce, 
especially in people with diabetes. We present here a 
comprehensive narrative review of the available literature 
to describe and synthesize epidemiology, pathophysiol-
ogy, screening, diagnosis, and therapeutics of LEAD in 
patients with diabetes.
Epidemiology and risk factors
Prevalence and incidence
LEAD affects over 200 millions people worldwide, 
including 40 millions living in Europe [5]. It is 2–4 times 
more frequent in people with type 2 diabetes than in the 
general population [3, 4]. The prevalence of LEAD varies 
across studies depending to differences in characteristics 
of the populations including LEAD definition, age, and 
ethnicity. Usually discovered during the 5th decade of 
life, the prevalence of LEAD increased exponentially after 
65  years of age. In the Action in Diabetes and Vascular 
Disease: PreterAx and DiamicroN Modified-Release 
Controlled Evaluation (ADVANCE) trial, the baseline 
prevalence of LEAD (defined as lower-limb amputation 
of at least one digit, chronic foot ulceration due to arte-
rial insufficiency, or peripheral revascularization proce-
dure) was estimated at 4.6% [10]. The LEAD prevalence 
was much higher and may exceed 20% when its definition 
was based on abnormal ankle–brachial index (ABI) [2, 4, 
11]. The prevalence increases also with rising duration of 
diabetes as shown in the UK Prospective Diabetes Study 
(UKPDS): 1.2% at diagnosis of diabetes and 12.5% after 
18 years of its evolution [12]. In the same manner, differ-
ent LEAD incidences were reported: 1.2 per 100 patient-
years in ADVANCE trial and 3.7 per 100 patient-years in 
an Australian cohort [2, 13].
Prognostic and risk factors
LEAD is one of the major causes of diabetic foot. It 
was present in 49% of patients with diabetic foot in the 
EURODIALE study, and one-third of participants had 
both LEAD and infection [14]. Diabetic patients with 
LEAD, compared with those without LEAD, have also 
a higher risk of CVD, and cardiovascular and all-cause 
mortality [2, 10, 11, 15]. The key risk factors are similar to 
those related to CVD, including age, sex, tobacco smok-
ing, systolic blood pressure, and plasma concentrations 
of lipids [12, 13, 16]. A recent study has suggested that 
the leg fat distribution may be used as a potential marker 
for predicting CVD [17].
Microvascular disease, mainly macroalbuminuria and 
diabetic retinopathy, have been shown to be independ-
ent risk factors for LEAD [13, 16]. Furthermore, a recent 
large epidemiological study has shown that low glomer-
ular filtration rate and pathological albuminuria were 
independently associated with excess risk of LEAD [18]. 
The risk of LEAD may also vary according to differences 
in region of origin. In ADVANCE study, the incidence 
of major LEAD was lesser in Asians compared with par-
ticipants from Eastern Europe or Established Market 
economies [13]. Despite a higher rate of CVD, people 
from South Asia, compared with white Europeans, have 
a lower prevalence of LEAD [19]. The explanation of this 
paradox has not yet been clearly elucidated, and genetic 
predisposition to LEAD may be suspected.
Pathophysiological mechanisms
Intermittent claudication results from a diminished inflow 
of oxygen due to a reduced blood flow in the lower limbs 
during physical activity, which is a consequence of steno-
sis or obstruction of an artery irrigating the skeletal muscle 
[20]. Many mechanisms contribute to the development of 
LEAD, in particular arterial stiffness, thrombotic abnor-
malities, low-grade inflammation, advanced glycation 
end-products, and oxidative stress (Fig.  1) [21–23]. Sev-
eral studies have suggested the development of an acute 
inflammatory reaction in response to ischemia induced 
by exercise, with increased release of different biomark-
ers (thromboxane, interleukin 8, intercellular adhesion 
molecules, or von Willebrand factor) and vasoconstrictors 
including endothelin-1 [24]. We have recently reported an 
independent association between plasma concentrations of 
tumor necrosis factor-α receptor 1 (TNRF1) and ischemia-
modified albumin, inflammatory and redox status biomark-
ers, and an excess-risk of major LEAD in patients with type 
2 diabetes [25]. Interestingly, TNFR1 improves the predic-
tion of LEAD over the traditional risk factors.
Endothelial cells play an important role in vascular biol-
ogy based on their strategic location between blood and 
tissues. They secrete many paracrine factors in the vascu-
lar wall and its lumen. In pathological setting, endothelial 
dysfunction induces structural, hemodynamic, and func-
tional vascular abnormalities, altering blood vessels reac-
tivity and relaxation, and generating atherosclerosis [26]. 
Endothelial dysfunction and increased arterial wall stiff-
ness play an important role in the pathogenesis of LEAD 
in individuals with diabetes [27, 28].
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LEAD has clearly been identified as a common 
manifestation of atherosclerosis of the large ves-
sels [29]. However, recent studies provided evidence 
for the implication of microvascular dysfunction in 
the pathogenesis of macrovascular disease includ-
ing LEAD [30–32]. An Italian study has shown micro-
vascular histological changes including expansion of 
the basal membrane and a reduced capillary density 
in neuro-ischaemic diabetic feet with revasculariza-
tion requirement [32]. In the ADVANCE study, the 
baseline history of microvascular disease (defined 
as the presence of macroalbuminuria (urinary albu-
min to creatinine ratio > 300  mg/g), requirement of 
retinal photocoagulation therapy, proliferative retin-
opathy, macular oedema, or diabetes-related blind-
ness) was independently associated with excess risk 
of major LEAD during follow-up [13]. Interestingly, 
microvascular disease was associated with distal LEAD 
manifestations (lower-limb ulceration or amputation 
induced by vascular disease) whereas macrovascular 
disease (defined as the presence of myocardial infarc-
tion, stroke, coronary artery bypass graft, percutaneous 
transluminal coronary angioplasty, or hospital admis-
sion for unstable angina or transient ischaemic attack) 
was linked to proximal presentation (requirement of 
peripheral revascularization). On the other hand, the 
baseline history of LEAD was associated with increased 
risk of advanced diabetic retinopathy, but not with the 
incidence of end-stage renal disease [10]. Patients with 
both major LEAD and chronic kidney disease (CKD) 
may have died before experiencing more advanced kid-
ney endpoints. Of note, a previous study has reported a 
very high rate (70–80%) of death during 4 years of fol-




The American Diabetes Association (ADA) recommends 
(Table  1) an initial screening for LEAD based on an 
exhaustive interview and a clinical examination includ-
ing a history of decreased walking speed, leg fatigue, 
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Fig. 1 Principal mechanisms involved in the pathogenesis of lower‑extremity artery disease in patients with diabetes
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Diabetic neuropathy may hide symptoms of LEAD, and 
should be systematically screened as well. Distal diabetic 
neuropathy is also involved in medial arterial calcification 
that leads to incompressible arteries [35, 36]. The clinical 
presentation of LEAD can be assessed according to Ler-
ich and Fontaine or Rutherford classification [37]. IC and 
rest pain are the most important signs to be evaluated, 
though they can be lacking or difficult to attribute exclu-
sively to LEAD. Any deterioration of walking quality or 
speed must be taken into account as well as fatigue, pain, 
cramps, discomfort or burns in buttocks, thighs, calfs or 
feet. Those symptoms are especially suggestive of LEAD 
when triggered by exercise and quickly relieved with 
rest. The clinical examination may also contain a careful 
evaluation of the general aspect of the skin, hairiness, and 
lower limb temperature. Pulse palpation (distal pedis, 
posterior tibial, popliteal and femoral arteries), a simple 
and cheap clinical examination, should be systematically 
performed in all patients with diabetes [34]. Nonetheless, 
pulse palpation is not a reliable test; it depends on ana-
tomic variations, physician experience, and examination 
conditions [38, 39]. Pulse palpation has a weak diagnostic 
performance [40–42], particularly the dorsal pedis pulse, 
which can be absent without any vascular abnormalities. 
However, the absence of both distal pedis and tibial pos-
terior pulses during satisfying exam conditions improve 
the performance [38, 43].
Ankle–brachial index testing
Ankle–brachial index has emerged as the relatively sim-
ple, non-invasive, and inexpensive tool for LEAD diag-
nosis [44]. The ADA recommends the assessment of ABI 
as a first line non-invasive test in patients with symp-
toms or signs of LEAD [34]. It is computed as a ratio of 
systolic blood pressure at the ankle to the systolic blood 
pressure in the upper arm. ABI is normal in 1.0–1.4 
range, suspicious in 0.9–1 range, and obviously patho-
logic under 0.9. An ABI over than 1.4 is also considered 
as abnormal, reflecting calcified and stiffed arteries. ABI 
was also reported as a marker of CVD and death [45], 
but the latest US Preventive Services Task Force (USP-
STF) recommendation (Table  1) has underlined the 
lack of evidence supporting the ABI use to screen for 
LEAD and cardiovascular risk in asymptomatic adult 
people [46]. The performance of ABI for LEAD screen-
ing is particularly inconsistent in people with diabetes 
[47, 48]. A comprehensive systematic review showed a 
variable performance: the sensitivity of ABI < 0.9 ranged 
from 29 to 95% (median at 63%), and its specificity var-
ied between 58 and 97% (median 93%). The addition of 
ABI > 1.3 did not improve the discrimination. The meas-
urement of ABI is also dependent on operator skills [49]. 
The performance is particularly affected by the presence 
of peripheral diabetic neuropathy, medial arterial calci-
fication, and incompressible arteries. In these situations, 
the toe brachial index may be more effective (pathologi-
cal if < 0.70). The quality of studies evaluating alternative 
diagnostic techniques for the screening of LEAD in indi-
viduals with diabetes is poor. Otherwise, the toe pressure 
and the transcutaneous pressure of oxygen (TcPO2) are 
recommended for the diagnosis of lower limb critical 
ischemia (see below), and the estimation of the likelihood 
of wound healing or a requirement of amputation.
Ultrasound and other imaging methods
The Doppler ultrasound exam is an imaging method with 
a good LEAD diagnosis performance (sensitivity 93% and 
specificity 97%) [50]. It is a simple, non-invasive, and an 
affordable method allowing anatomical and hemody-
namic vascular assessments, regardless of medial arterial 
calcifications, but it remains dependent on the operator 
experience. The Doppler waveform analysis provides fur-
ther information; a triphasic waveform reflects a normal 
hemodynamic state and then the absence of LEAD. The 
presence of monophasic or biphasic waveforms has a 
good negative predictive value but her positive predictive 
value remains less consistent depending on the presence 
of peripheral neuropathy [51]. Interestingly, a previous 
Table 1 Publications of the major international guidelines in screening, diagnosis, and treatment of lower-extremity 
artery disease
Society Guidance Journal Year References
American Diabetes Association Microvascular complications and foot care: standards of medical care in diabetes Diabetes Care 2018 [34]
US Preventive Services Task Force Screening for peripheral artery disease and cardiovascular disease risk assess‑
ment with the ankle–brachial index
JAMA 2018 [46]
American Heart Association & 
American College of Cardiol‑
ogy
Management of patients with lower extremity peripheral artery disease Circulation 2017 [84]
European Society of cardiology & 
European Society for Vascular 
Surgery
Diagnosis and treatment of peripheral arterial diseases Eur Heart J 2018 [90]
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study has shown that a semiquantitative score based on 
the ultrasonographic features of the lower limb arter-
ies may help in the assessment of LEAD across different 
stages, as well as the evaluation of its associated cardio-
vascular risk [52]. A recent finding suggested that this 
score might be better than ABI to screen LEAD [53].
The computed tomography angiography, magnetic 
resonance angiography and angiography permit a pre-
cise topographic diagnosis and are often performed in 
the pre-operative work-up when large arterial vessels are 
involved. The topography of LEAD is usually categorized 
as proximal (from the common iliac to the superficial 
femoral artery) and distal lesions (from the popliteal to 
the dorsal pedis artery). The distal localisation has been 
shown to be more common than the proximal one in 
patients with diabetes [54].
Critical limb ischemia
The critical limb ischemia (CLI) is defined as the presence 
of ischaemic chronic rest pain (> 2 weeks) typically in the 
forefoot with or without ischaemic lesions or gangrene 
due to arterial occlusive disease. It is considered as the 
last stage of LEAD spectrum, with excessively high risk 
for CVD and death [55]. The CLI is frequent in patients 
with diabetes, and it may be suspected even in the 
absence of pain in patients with peripheral diabetic neu-
ropathy. The diagnosis of CLI is confirmed based on one 
of the following: ABI < 0.4, ankle pressure < 50  mmHg, 
toe pressure < 30  mmHg or TcPO2 < 30  mmHg. Acute 
limb ischemia, an emergency condition, needs an urgent 
diagnosis to evaluate the odds of the limb salvage and to 
determine the requirement of medical and surgical treat-
ments. The wound ischemia and foot infection (WIFI) 
classification has been recently recommended by the 
society of vascular surgery (SVS); it provides a risk strati-
fication based on the severity of the wound, ischemia, 
and foot infection [56].
Therapeutic strategies
The management of LEAD in patients with diabetes 
requires a multidisciplinary team including endocri-
nologist, vascular surgeon, infectious disease specialist, 
radiologist, rehabilitation doctor, nurse, and podiatrist. 
Despite the high macrovascular risk, the based-evidence 
prevention therapies remain underused in diabetic 
patients with LEAD compared to their counterparts 
with coronary or cerebrovascular disease [57, 58]. There-
fore, a considerable proportion of patients with diabetes 
and LEAD remain at increased risk for CVD as well as 
overall adverse events [2]. A strict control of cardio-
vascular risk factors is crucial to manage LEAD, and to 
improve the cardiovascular and the overall prognosis of 
each patient.
Anti-diabetic treatment
Intensive versus standard glucose control
Epidemiological studies and RCTs showed the efficiency 
of intensive blood glucose control in the reduction of the 
development and progression of long-term microvascu-
lar complications (diabetic nephropathy, retinopathy, and 
neuropathy) in patients with diabetes [59–61]. However, 
the benefit of intensive glucose control in the prevention 
of CVD and death has not been clearly established, and 
its effect on the risk of LEAD has been rarely addressed 
in the literature. In the UKPDS trial, each 1% reduction 
in HbA1c was associated with a 43% decreased risk of 
major LEAD (amputation or death following a peripheral 
vascular event) [62]. However, this benefit did not persist 
during the post-trial observational period of the UKPDS 
study [63]. In the ADVANCE trial, the incidence of major 
LEAD (lower-limb ulceration, amputation, revasculariza-
tion requirement, or death induced by peripheral arterial 
disease) was comparable among randomized study arms 
(intensive versus standard glucose control) [13, 61]. A 
recent systematic review and meta-analyses (with a low 
level of evidence) displayed 35% reduction of LLA risk in 
patients with type 2 diabetes assigned to intensive glycae-
mic control compared with those assigned to less inten-
sive strategy, but no effect was observed on ischemic 
disease [64].
Insulin‑sensitizing versus insulin‑providing therapy
The PROspective pioglitAzone Clinical Trial In macro-
Vascular Events (PROactive) trial showed a non-signifi-
cant association between use of pioglitazone, an agonist 
of peroxisome proliferator-activated receptor γ (PPAR 
γ), and a higher risk of leg revascularization, compared 
with placebo [65]. However, the post hoc analyses of 
the Bypass Angioplasty Revascularization Investiga-
tion in Type 2 Diabetes (BARI-2D) trial displayed lower 
incidence of LEAD (new low ABI ≤ 0.9, lower-extremity 
revascularization or LLA) among patients assigned to 
insulin-sensitizing therapy (metformin or thiazolidinedi-
one) compared with those assigned to insulin-providing 
therapy (sulfonylureas, repaglinide, nateglinide or insu-
lin) [66]. Furthermore, another observational study has 
shown that the use of metformin was associated with a 
lower prevalence of below-the-knee arterial calcification 
[67].
New anti‑diabetic agents
After concerns about the cardiovascular safety of some 
anti-diabetic drugs, the US Food and Drug Administra-
tion (FDA) implemented a guidance statement in 2008 
recommending cardiovascular safety trial of each new 
anti-diabetic agent. Thus, several RCTs were conducted 
worldwide and demonstrated the non-inferiority of 
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some new inhibitors of dipeptidyl peptidase 4 (DPP-4) 
or glucagon-like peptide-1 (GLP-1) receptor agonists, 
compared with placebo in patients with type 2 diabetes 
[68–71]. Interestingly, other trials have shown cardio-
vascular benefit of some GLP-1 receptor agonists (lira-
glutide, semaglutide, and albiglutide) or sodium glucose 
co-transporter 2 (SGLT2) inhibitors (empagliflozin and 
canagliflozin) [72–76]. In contrast to cardiovascular and 
cerebrovascular endpoints, LEAD was not fully investi-
gated in these studies. Although, Marso et al. reported in 
the SUSTAIN-6 trial, that participants treated by sema-
glutide, a prolonged action GLP-1 receptor agonist, had 
a significant 35% lower risk of coronary and peripheral 
revascularization, but with no specific data dedicated to 
lower-limb procedures [73]. A recent post hoc analysis of 
the liraglutide effect and action in diabetes: evaluation of 
cardiovascular outcome results (LEADER) trial displayed 
a fewer LLA rate among patients with diabetic foot 
assigned to liraglutide, compared with those assigned to 
placebo [77]. This difference seemed to be driven mainly 
by major amputation rather than minor amputation, but 
there was no difference between study arms in diabetic 
foot requiring peripheral revascularization. The inci-
dence of LEAD was similar among study arms (exenatide 
versus placebo) in the Exenatide Study of Cardiovascular 
Event Lowering (EXCEL) trial [78]. Notably, the Canagli-
flozin Cardiovascular Assessment Study (CANVAS) trial 
has shown a twofold higher risk of LLA in participants 
assigned to canagliflozin, compared with those assigned 
to placebo [75]. This increased risk of amputation has 
been mainly driven by vascular disease, while the rate of 
diabetic neuropathy seemed to be lower in the canagli-
flozin group than in the placebo arm (CANVAS Program 
Collaborative Group, the 53rd Annual Meeting of the 
European Association for the Study of Diabetes, Lisbon, 
15 September 2017; https ://www.easd.org/progr amme-
glanc e.html). The pathophysiological mechanisms likely 
to explain the high risk of LLA associated with cana-
gliflozin in the CANVAS trial have not yet been estab-
lished. It remains unclear if the risk of amputation is a 
class effect for all SGLT-2 inhibitors. While some studies 
suggested association with different SGLT-2 inhibitors 
and increased risk of LLA [79–81], the secondary anal-
yses of the EMPA-REG OUTCOME trial have shown a 
similar incidence of LLA in empagliflozin versus placebo 
group [82]. Furthermore, a recent large real-life study 
conducted in the USA did not show association between 
SGLT2 inhibitors and the risk of LLA [83].
Antihypertensive drugs
The American Heart Association (AHA) and the Ameri-
can College of Cardiology (ACC) recommend antihy-
pertensive treatment in patients with LEAD to decrease 
cardiovascular events and stroke (Table  1) [84], but the 
benefit-risk of each antihypertensive class in term of 
LEAD-related events has not yet been fully investigated 
even in the general population [85]. The relationship 
between blood pressure and LEAD is not simple, and 
may be U-shaped in the general population [86]. In the 
type 2 diabetes setting, the risk of LEAD increased with 
rising systolic blood pressure and decreasing diastolic 
blood pressure, and is particularly associated with grow-
ing pulse pressure [13], which is known as a surrogate 
of arterial stiffness [87]. Interestingly, each 10  mmHg 
decrease of systolic blood pressure was associated with 
16% reduction of LEAD risk in the observational period 
of the UKPDS study [88]. The post hoc analyses of the 
Veterans Affairs Diabetes (VADT) trial have also shown 
a reduction of the ischemic LLA rate in participants 
with systolic blood pressure < 140 versus ≥ 140  mmHg 
[89]. However, the ADVANCE trial has not reported any 
LEAD benefit related to perindopril/indapamide treat-
ment, compared with placebo [13].
Lipid lowering drugs
Statin therapy
The European Society of Cardiology (ESC) and the 
European Society for Vascular Surgery (ESVS) recom-
mended targeting serum low-density lipoprotein cho-
lesterol (LDL-C) less than 1.8  mmol/L (< 70  mg/dL) or 
decreased by ≥ 50% if the initial value is between 1.8 
and 3.5 mmol/L (70 and 135 mg/dL) for all patients with 
LEAD (Table 1) [90]. Although the lack of specific evalu-
ations of the effects of lipid-lowering drugs on the occur-
rence of LEAD-related endpoints, observational studies 
and few RCTs provide evidence for reductions of cardio-
vascular events and all-cause mortality in patients using 
statins [91–93]. In the Reduction of Atherothrombosis 
for Continued Health (REACH) registry, statin use was 
associated with a 17% decrease in adverse cardiovascular 
events rates among individuals with LEAD, without het-
erogeneity regarding diabetes status [94]. Other studies 
have also suggested that statin may reduce the LLA inci-
dence and improve walking distance in patients suffering 
for IC [95–98].
Fibrate therapy
The use of Fenofibrate failed to reduce macrovascular 
events in participants with type 2 diabetes in the Action 
to Control Cardiovascular Risk in Diabetes (ACCORD) 
and the Fenofibrate Intervention and Event Lowering 
in Diabetes (FIELD) trials [99, 100]. However, second-
ary analyses of the FIELD trial displayed a 36% reduc-
tion in the risk of LLA (a pre-specified tertiary endpoint) 
in participants assigned to fenofibrate, compared with 
those assigned to placebo [101]. This protection has been 
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especially driven by decreased risk of minor amputation 
without known large-vessel disease rather than amputa-
tion with large-vessel lesions.
PCSK9 inhibitors
Despite the availability of effective drug therapies that 
reduce LDL-cholesterol, CVD remains an important 
cause of mortality and morbidity. Therefore, additional 
LDL-cholesterol reduction may be warranted, especially 
for patients who are unresponsive to, or unable to take, 
existing LDL-cholesterol reducing therapies. Proprotein 
convertase subtilisin/kexin type 9 (PCSK9) is a serin pro-
tease with effect on the LDL receptor cycle leading to its 
degradation and therefore inhibition of continuing LDL-
cholesterol clearance from the blood. This path is the 
target of newly developed lipid-lowering drugs, PCSK9 
inhibitors, monoclonal antibodies leading to further LDL-
cholesterol decrease, with reducing CVD risk, but not 
cardiovascular or all-cause mortality [102]. The Further 
Cardiovascular Outcomes Research with PCSK9 Inhibi-
tion in Subjects with Elevated Risk (FOURIER) trial has 
shown that evolocumab, versus placebo, reduced LDL-
cholesterol and adverse cardiovascular events among 
patients with elevated cardiovascular risk on statin ther-
apy [103]. Evolocumab decreased cardiovascular end-
points reliably in participants with and without diabetes at 
baseline [104]. The use of Evolocumab was also associated 
with 42% reduction of LEAD-related events (acute limb 
ischemia, major amputation, or urgent peripheral revas-
cularization for ischemia) with consistent effects in those 
with or without known LEAD at baseline [105]. There was 
a consistent relationship between lower achieved LDL-
cholesterol and reduced risk of LEAD-related events.
Antiplatelet and anticoagulation therapies
Antiplatelet therapy in symptomatic or asymptomatic 
LEAD
Antiplatelet drugs are advised in all patients with symp-
tomatic LEAD or having undergone previous vascular 
revascularization, to reduce both CVD and peripheral 
vascular event. The ESC and the ESVS guidelines did not 
recommend antiplatelet therapy in subjects with asymp-
tomatic LEAD (Table 1) [90]. In the general population, 
aspirin, compared with placebo, did not reduce vascular 
events among participants with asymptomatic LEAD 
[106]. Furthermore, the prevention of progression of 
arterial disease and diabetes (POPADAD) trial did not 
provide evidence to support the use of aspirin or antioxi-
dant agents in the primary prevention of macrovascular 
events (including amputation above the ankle for critical 
limb ischaemia) in 1276 diabetic patients with asympto-
matic LEAD [107].
Single antiplatelet therapy
The meta-analyses from the Antithrombotic Trialists 
Collaboration group showed that aspirin (or another oral 
antiplatelet drug) was protective in different high vascular 
risk populations, including those with LEAD [108]. How-
ever, some data might encourage the use of clopidogrel 
rather than aspirin in LEAD condition, especially in peo-
ple with diabetes. A meta-analysis of 18 RCTs comparing 
aspirin to placebo in 5269 patients with symptomatic or 
asymptomatic LEAD did not show a significant reduction 
in cardiovascular adverse events, except for non-fatal 
stroke considered individually as a secondary endpoint 
[109]. No significant association was observed between 
aspirin treatment and the other secondary outcomes 
including all-cause or cardiovascular mortality, myocar-
dial infarction, or major bleeding. The aspirin in patients 
at risk of ischaemic events (CAPRIE) trial, involving 20% 
of participants with diabetes, has displayed reduction of 
the risk of LEAD-related events in participants assigned 
to clopidogrel 75  mg compared with those assigned to 
aspirin 325  mg [110]. Finally, treatment by Ticagrelor 
(90 mg twice daily) has not been shown to be superior to 
clopidogrel (75 mg once daily) for the reduction of car-
diovascular or limb events in 13,885 participants (38% of 
whom had diabetes) with symptomatic LEAD [111].
Dual antiplatelet therapy
No evidence exists for any benefit related to a dual anti-
platelet therapy in patients with LEAD. In the post hoc 
analyses of the Clopidogrel for High Atherothrombotic 
Risk and Ischemic Stabilization, Management, and 
Avoidance (CHARISMA) trial, dual therapy (clopidogrel 
and aspirin) did not provide further vascular protec-
tion over aspirin alone in LEAD patients (36% with dia-
betes), except for the risk of myocardial infarction and 
hospitalization for ischaemic events [112]. This modest 
beneficial effect of dual therapy was counterbalanced by 
an increased risk of bleeding. Some groups suggest the 
use of dual antiplatelet therapy for at least 1 month after 
endovascular therapy for LEAD with a stent implantation 
irrespective of its type [90].
Anticoagulant therapy
Anticoagulation strategy is currently advisable in the 
presence of its traditional indication (e.g. atrial fibrilla-
tion), although new drugs have provided encouraging 
findings for LEAD-related events. The cardiovascular 
outcomes for people using anticoagulation strategies 
(COMPASS) trial showed that rivaroxaban, an oral fac-
tor Xa inhibitor, plus aspirin was associated with fewer 
adverse cardiovascular events, but more major bleeding 
events versus aspirin alone [113]. The rivaroxaban treat-
ment was also associated with reduced major limb events 
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in patients with carotid or lower-limb peripheral artery 
disease. This benefit was reliable in participants with or 
without diabetes at baseline [114]. The Trial to Assess 
the Effects of SCH 530348 in Preventing Heart Attack 
and Stroke in Patients With Atherosclerosis (TRA2°P-
TIMI 50) revealed that Vorapaxar, a novel antagonist 
of protease-activated receptor-1, reduced the rates of 
hospitalization for acute limb ischemia and peripheral 
artery revascularization, but did not reduce the risk of 
cardiovascular death, myocardial infarction, or stroke in 
patients with stable atherosclerotic vascular disease and 
LEAD [115]. The Vorapaxar use was also associated with 
an increased risk of bleeding. These new therapies may 
improve the management of patients with LEAD, but the 
excess risk of bleeding should be seriously considered.
Multifactorial intervention therapy
The Steno2 trial has compared a multifactorial inter-
vention versus conventional treatment in patients with 
type 2 diabetes and microalbuminuria [116]. During the 
7.8-year in-trial period, Gæde and co-workers observed 
a fewer number of LLA (7 versus 14) and surgical pro-
cedures for peripheral atherosclerotic artery disease (6 
versus 12) in participants assigned to multifactorial ver-
sus conventional therapy. These benefits persisted during 
the 5.5-year observational post-trial period [117]. On the 
other hand, no difference was observed in term of lower 
limb vascular events (amputation or revascularisation) in 
the Japan Diabetes Optimal Treatment study for 3 major 
risk factors of cardiovascular diseases (J-DOIT3) that 
compared the effectiveness and safety of a multifactorial 
intervention for control of glucose, blood pressure, and 
LDL cholesterol, versus strategy based on the ongoing 
Japanese guidelines in patients with type 2 diabetes [118].
Other vasodilator therapies
Some vasodilator agents may be used to relieve inter-
mittent claudication and increase walking distance in 
patients with LEAD. The cilostazol, a selective inhibitor 
of the phosphodiesterase III, is the most studied drug; 
its benefit is modest with no evidence for vascular pro-
tection. In a comprehensive meta-analyses, cilostazol 
improved walking distance with no relevant cardio-
vascular effect or improvement in quality of life [119]. 
This vasodilator is responsible for some adverse effects 
including headaches, vertigo, palpitations, and diarrhea. 
The cilostazol also acts as an antiplatelet drug and there-
fore must be associated cautiously with other antiplate-
let drugs or anticoagulant agents [120]. Naftidrofuryl, a 
peripheral vasodilator, also improved significantly the 
walking distance [121]. Finally, Buflomedil, a vasoac-
tive agent, has only a small benefit in term of IC, and has 
been linked to some safety concerns including lethal and 
non-lethal neurologic and cardiovascular events in cases 
of accidental and voluntary overdoses [122].
Innovating treatment
Growth factor therapy
Some data suggested a relationship between circulating 
levels of growth factors and the development of LEAD 
[123]. The therapies using growth factors, delivered 
directly (as recombinant proteins), or indirectly (e.g. by 
viral vectors or DNA plasmids encoding these factors), 
have been tested in LEAD with contrasting findings. The 
Efficacy and Safety of XRP0038/NV1FGF in Critical Limb 
Ischemia Patients With Skin Lesions (TA-MARIS) trial 
did not show relevance of non-viral 1 fibroblast growth 
factor in the reduction of death or LLA in 520 partici-
pants (53% with diabetes) with critical limb ischemia 
unable for revascularisation [124]. A recent meta-analysis 
of 14 RCTs investigating fibroblast, hepatocyte, and vas-
cular endothelial growth factors did not support their use 
in patients with LEAD in term of death, major amputa-
tion, or IC. However, these factors may improve haemo-
dynamic measurements and decrease the risk of minor 
amputation [125].
Stem cell therapy
Some studies have tested stem cell therapy in patients 
with LEAD with encouraging results, although the lack 
of definitive evidences. A recent systematic review of the 
literature and a meta-analysis have shown that autolo-
gous cell therapy reduced the risk of LLA and rest pain, 
improved wound healing, and increased ABI and TcPO2 
in patients with LEAD who were ineligible for surgical 
or percutaneous revascularization [126]. Interestingly, 
the benefit of cell therapy on LLA rate was higher in tri-
als with a high prevalence of diabetes at baseline. Cell 
therapy was not associated with severe adverse events. 
All benefits were especially observed in non-randomized 
studies and cell therapy versus standard care RCTs. How-
ever, these associated benefits were not significant in 
placebo-controlled randomized trials, and disappeared 
in RCTs with a low risk of bias. Further high-quality pla-
cebo-controlled randomized trials are needed to confirm 
the safety and the efficiency of autologous cell therapy in 
patients with LEAD. Of note, a recent placebo-compared 
RCT (Patients With Intermittent Claudication Injected 
With ALDH Bright Cells (PACE)) did not support the use 
of cell therapy in patients with LEAD [127]. PACE trial 
has not shown improvement in peak walking time, collat-
eral count, peak hyperaemic popliteal flow, and capillary 
perfusion in patients with LEAD treated by autologous 
bone marrow-derived aldehyde dehydrogenase bright 
cells.
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Other innovating procedure
Remote ischaemic conditioning (RIC), involving repeated 
applications of short periods of limb ischemia over days 
or weeks, may improve endothelial function, skin micro-
circulation, and regulates the inflammatory response. 
Some data suggested that repeat RIC may boost healing 
of ischaemic diabetic foot [128].
Lifestyle management
Smoking cessation
Tobacco smoking including second-hand smoke has been 
highlighted as one of the three leading risk factors for 
global disease burden worldwide [129]. It is an independ-
ent risk factor for LEAD [12, 13, 16], and has been shown 
as a significant predictor for worse outcomes includ-
ing peripheral events and death in patients with LEAD 
undergoing infra-inguinal bypass [130]. Tobacco smoking 
may induce prothrombotic and atherogenic abnormali-
ties, and increase the risk of acute myocardial infarc-
tion, sudden cardiac death, stroke, aortic aneurysm, and 
LEAD [131, 132]. Both passive and active smoking ces-
sation is required in all patients with peripheral arterial 
disease including LEAD. Health authorities should adopt 
effective public health policies limiting tobacco use, espe-
cially in low- and middle-income countries.
Exercise training
The exercise training improved walking ability, and dis-
tances, as well as physical function, vitality and general 
health [133]. However, the exercise training did not 
increase ABI, or reduce the risk of LLA, cardiovascu-
lar events, or mortality. Some data showed significant 
improvement in maximal and pain-free walking distance 
in participants assigned to supervised exercise therapy, 
compared with non-supervised exercise therapy regi-
mens [134]. No significant difference was observed in 
term of quality of life parameters between the two exer-
cise programs.
Nutrition therapy
Healthy diet might help to achieve and maintain body 
weight goals, reach individualized glycaemic, blood pres-
sure, and lipid targets, and delay or prevent diabetic 
complications, especially microvascular disease [135]. 
Previous studies suggested the influence of nutrient qual-
ity on the prevalence of LEAD [136, 137]. A systematic 
review suggested that Omega‐3 fatty acids might have 
modest haematological benefit in people with IC, but 
no improvement in walking distance, ABI, angiographic 
measurements, or quality of life [138]. Interestingly, 
a Spanish trial has suggested that the Mediterranean 
diet supplemented with extra-virgin olive oil or nuts, 
compared with a low-fat diet, was associated with a lower 
risk of LEAD [139].
Surgical or endovascular revascularization
Contrasting observations were reported in terms of peri-
operative outcomes in patients with diabetes undergoing 
revascularization [140–144]. Recent studies have shown 
similar peri- and post-operative mortality in patients 
with diabetes, compared with those without diabetes, but 
diabetic patients had a higher risk of incomplete wound 
healing and major amputation, a prolonged length of hos-
pital stay and more frequent readmission [143, 144]. Sur-
gical revascularization provides good long-term patency, 
although with a longer hospital stay and increased risk 
for perioperative complications and mortality, when 
compared with endovascular procedure [145]. The devel-
opment of new techniques last decades has encouraged 
the implementation of endovascular therapy in patients 
with LEAD. The different options of revascularization 
depend on several factors including anatomical loca-
tion, extension, and length of arterial lesions; general 
health condition of each patient and comorbidities; as 
well as centre and surgeon experience. The endovascu-
lar revascularization may be a good strategy for short 
(< 5 cm) stenosis or occlusion of iliac arteries, providing 
a good long-term patency [146]. Whereas, a hybrid pro-
cedure (endarterectomy or bypass at the femoral level 
combined with endovascular therapy) may be indicated 
for ilio-femoral lesions [147]. Aorto-femoral bypass is 
the first line strategy in aorto-iliac occlusions in patients 
who fit for surgery [148], while an endovascular proce-
dure should be considered in long or bilateral lesions in 
patients with severe comorbidities [145, 149]. An endo-
vascular revascularization may be also considered as a 
first strategy for aorto-iliac occlusive lesions if done by 
an experienced team without compromising subsequent 
surgical options [150]. In femoro-popliteal stenosis/
occlusions < 25  cm, an endovascular revascularization 
may be considered as the first-line therapy, and a primary 
stent implantation has been associated with further mor-
phological benefits [151, 152]. If the occlusion/stenosis is 
more than 25 cm, surgical bypass may be an appropriate 
option with a better long-term patency, especially when 
using the great saphenous vein. The infra-popliteal artery 
disease is a common LEAD presentation in patients with 
diabetes. The ESC and ESVS recommends endovascular 
therapy as first choice in infra-popliteal artery disease 
with stenotic lesions and short occlusions, while bypass 
with an autologous vein gives may be discussed for long 
occlusions (Table 1) [90]. However, endovascular therapy 
can be tried in patients with long occlusions if the surgi-
cal risk is judged as high, or in the absence of autologous 
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vein. The angiosome concept, targeting the ischaemic tis-
sues, may also be considered.
Conclusion
LEAD is one of the most severe conditions seen in 
patients with diabetes. It leads to excess risk of death, 
CVD, and limb loss, and is responsible for disabilities and 
an important socio-economical burden. The diagnosis 
strategy has been better codified now focusing in patients 
with evocative symptoms of LEAD, far from the worth-
less and expensive universal screening in asymptomatic 
patients. Anti-diabetic, anti-hypertensive, lipid-lowering 
and antiplatelet medications may improve the cardio-
vascular prognosis of patients with LEAD, but few has 
been done to test their benefits to reduce the occurrence 
and the progression of LEAD as well as lower-extremi-
ties adverse events. High quality studies are required to 
advance the knowledge in pathophysiology and natural 
history of LEAD, and to evaluate different aspects of its 
management.
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